Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial

Heiss, Brian; Geynisman, Daniel M.; Martinez, Elia; Wong, Alvin Seng Cheong; Yong, Wei Peng; Szmulewitz, Russell Z.; Stadler, Walter M.

doi:10.1007/s00520-021-06670-3

Cited by 4 publications

(20 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…66 The small RCT assessing abiraterone at two doses (1000 mg fasting and 250 mg with a low-fat meal) showed high initial adherence at 60 days and throughout the study for the lower dose group ( n = 19, 96.5% versus 97.9%, p = 0.35) but significantly reduced adherence for the standard higher dose arm at the point in which patients came off study compared to at 60 days ( n = 11, 98.2% versus 91.7%, p = 0.008). 51 The large two-armed study conducted by Suttmann et al 71 assessed the impact of AEMs including education, reminders, and counseling components on adherence assessed with Morisky Medication-Taking Adherence Scale-4 (MMAS-4) scores in patients receiving abiraterone plus prednisone from October 2013 to June 2018. 71 Three-month medium/low MMAS-4 scores were 6.4% versus 9.1% and 6-month scores were 7.1% versus 7.4% among patients completing the MMAS-4 who received AEM ( n = 265) versus those not receiving AEM ( n = 212) with a 10-month median duration of treatment.…”

Section: Resultsmentioning

confidence: 99%

Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review

et al. 2023

View full text Add to dashboard Cite

Background: Orally administrated agents play a key role in the management of prostate cancer, providing a convenient and cost-effective treatment option for patients. However, they are also associated with adherence issues which can compromise therapeutic outcomes. This scoping review identifies and summarizes data on adherence to oral hormonal therapy in advanced prostate cancer and discusses associated factors and strategies for improving adherence. Methods: PubMed (inception to 27 January 2022) and conference databases (2020–2021) were searched to identify English language reports of real-world and clinical trial data on adherence to oral hormonal therapy in prostate cancer using the key search terms ‘prostate cancer’ AND ‘adherence’ AND ‘oral therapy’ OR respective aliases. Results: Most adherence outcome data were based on the use of androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (mCRPC). Self-reported and observer-reported adherence data were used. The most common observer-reported measure, medication possession ratio, showed that the vast majority of patients were in possession of their medication, although proportion of days covered and persistence rates were considerably lower, raising the question whether patients were consistently receiving their treatment. Study follow-up for adherence was generally around 6 months up to 1 year. Studies also indicate that persistence may drop further with longer follow-up, especially in the non-mCRPC setting, which may be a concern when years of therapy are required. Conclusions: Oral hormonal therapy plays an important role in the treatment of advanced prostate cancer. Data on adherence to oral hormonal therapies in prostate cancer were generally of low quality, with high heterogeneity and inconsistent reporting across studies. Short study follow-up for adherence and focus on medication possession rates may further limit relevance of available data, especially in settings that require long-term treatment. Additional research is required to comprehensively assess adherence.

show abstract

Section: Resultsmentioning

confidence: 99%

Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Based on a different methodology as described previously, results from a 2-arm prospective randomized trial conducted at 6 sites in the US and Singapore indicated that adherence to AA prescribed for metastatic PC using validated adherence questionnaires was measured at 91.69%-98.18% depending on the medication dose and schedule. 21…”

Section: Adherence To Oral Antiandrogen Therapies In Pcmentioning

confidence: 99%

“…20 Based on a different methodology as described previously, results from a 2-arm prospective randomized trial conducted at 6 sites in the US and Singapore indicated that adherence to AA prescribed for metastatic PC using validated adherence questionnaires was measured at 91.69%-98.18% depending on the medication dose and schedule. 21 Treatment adherence was also high in 193 patients with nonmetastatic CRPC initiated on apalutamide, a recently approved oral antiandrogen therapy. The study was conducted using electronic medical records representing 63 US urology practices from February 14, 2018 (FDA approval) to October 4, 2019.…”

Section: Adherence To Oral Antiandrogen Therapies In Pcmentioning

confidence: 99%

“…22 In general, adherence to oral antiandrogen therapies can be affected by factors such as: age, ethnicity, chemotherapy use, high prescription costs, radiological response, as well as medication dose, form, and schedule. 17,[19][20][21][23][24][25] However, worldwide studies using different methodologies revealed overall high adherence to oral antiandrogen therapies in PC patients.…”

Section: Adherence To Oral Antiandrogen Therapies In Pcmentioning

confidence: 99%

See 1 more Smart Citation

Adherence to Hormonal Therapies in Prostate Cancer

Hafron,

Sangha,

Kung

et al. 2023

Urology Practice

View full text Add to dashboard Cite

Introduction: Hormonal therapy is the standard of care in prostate cancer treatment. The approval of the first oral androgen deprivation therapy, relugolix, to treat prostate cancer patients provides an opportunity to review adherence to oral and injectable/implantable hormonal therapies to aid patients and physicians in making informed decisions.Methods: A PubMed search for available literature on adherence to hormonal therapy in prostate cancer was conducted, including published data on relugolix.Results: Adherence to oral antiandrogen therapy was above 90% by medication possession ratio in several studies worldwide and from 75% to 91% by proportion of days covered. For injectable/implantable androgen deprivation therapy, adherence to treatment ranged from 71% to 95%. In general, 60% and 29% of injections were reported to be delayed by more than 1 week and 2 weeks, respectively, with some patients experiencing testosterone increases (tests above 50 ng/dL). Although real-world data on adherence to relugolix are currently unavailable, pharmacokinetic/pharmacodynamics models demonstrated that, if necessary, treatment interruption up to 7 days would still maintain testosterone suppression levels. Conclusions:In general, adherence to hormonal therapy is high in prostate cancer. Studies revealed that adherence to injectable androgen deprivation therapy dosing schedules is important to maintain castrate levels. Pharmacokinetic/pharmacodynamics models showed that relugolix treatment interruption up to 7 days had minimal impact on testosterone suppression levels.

show abstract

“…PSA response rate: A decline of PSA ≥50%. CRPC, castration-resistant prostate cancer; PSA, prostate-specific antigen; PFS, progression free survival; OS, overall survival; po, oral; QD, quaque die; QAM, every morning; QPM, every evening; BID, twice daily; ivgtt, intravenous drip; ONCE, only once.docetaxel, cabazitaxel, Ra-223, orteronel, dutasteride, and apalutamide(77)(78)(79)(80)(81)(82)(83)(84)92,93,95,96). Yu et al(88) evaluated the effectiveness of intravenous apatorsen with oral prednisone (5 mg, twice daily) or prednisone alone, and observed a PSA decrease ≥50% in 47% of patients in the apatorsen with prednisone group compared to a decrease of 24% in the prednisone only group.…”

mentioning

confidence: 99%

A narrative review of the role of glucocorticoid receptors in prostate cancer: developments in last 5 years

Zhou¹,

Shi²,

Zhao³

et al. 2022

Transl Androl Urol

View full text Add to dashboard Cite

Background and Objective: Glucocorticoids, secreted from the adrenal gland, are commonly used in the treatment of castration-resistant prostate cancer (CRPC) because of their anti-inflammatory and antitoxic effects. However, glucocorticoids have been reported to have the opposite effects within the course of treatment. Many studies have shown that glucocorticoid receptors (GRs) are involved in the establishment of a dominant population of androgen-independent malignant cells, which may result in CRPC. In this review, we summarized the mechanisms of GRs in CRPC and the clinical application of glucocorticoids based on the present evidence. Methods:We summarized the isoforms of GRs and the mechanisms involved in CRPC. An updated literature search was performed from the ClinicalTrials database, the National Center for Biotechnology Information database and European Union Drug Regulating Authorities Clinical Trials database. The focus was on the timeframe from 2017 to 2022. At least one primary or secondary outcome [prostate-specific antigen (PSA) response rate, progression-free survival (PFS) or overall survival (OS) and median time to PSA progression] according to studies should be included.

show abstract

Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial

Cited by 4 publications

References 27 publications

Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review

Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review

Adherence to Hormonal Therapies in Prostate Cancer

A narrative review of the role of glucocorticoid receptors in prostate cancer: developments in last 5 years

Contact Info

Product

Resources

About